Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

A key chemical used in many gel nail polish products has been banned in England, Wales and Scotland.

The “gel nail ban” applies to one ingredient — Trimethylbenzoyl Diphenylphosphine Oxide, commonly known as TPO. It is used in some gel manicures to help the polish achieve a glossy finish and cure properly.

What Is TPO?

TPO (Trimethylbenzoyl Diphenylphosphine Oxide) is a photoinitiator commonly used in UV- and LED-cured nail products. It makes the varnish more durable and helps it hold its color for longer.

When Did the Gel Nail Ban Start?

The European Union banned TPO in cosmetic products from September 1, 2025. In the UK, the ban came into effect on August 15.

The ban means manufacturers can no longer sell new products containing TPO. However, salons can continue to offer gel manicures using existing TPO-containing products until February 14, 2027, or until their stocks run out.

Nail technicians will not be able to purchase new stock containing TPO. TPO-containing products continue to be used in the US, Australia and Asia.

Why Has TPO Been Banned in the UK?

The ban follows several animal studies that linked TPO to long-term fertility damage and reproductive issues.

Caroline Rainsford, Director of Science at The Cosmetic, Toiletry and Perfumery Association (CTPA), said the EU ban was based on the chemical's hazardous properties and how a substance might behave in a “worst-case” situation when the body is exposed to a very large amount.

“This is not how TPO is used in cosmetics. The amount of this ingredient used in nail products is over a thousand times less than the amount which could have any negative effect on fertility, and these products are applied to the nail, so the potential for the ingredient to be absorbed into our bodies is even smaller,” Rainsford was quoted as saying in media reports.

What Will Salons Use Instead?

TPO is used only in some gel polishes and is not found in traditional air-dried nail polishes. There are already TPO-free gels on the market, and many salons use these products. While some alternatives may belong to the same chemical family, different compounds have different safety ratings.

TPO-free gel systems now use alternative photoinitiators that meet regulatory standards while still delivering similar results.

TPO-free options are available across:

• Gel polish
• Builder gels
• BIAB-style systems
• Extension and overlay products

How to Maintain Healthy Nails

• Include foods rich in omega-3 fatty acids, lean proteins, and iron.
• Hydrate your nails with regular moisturizing to keep them from becoming brittle.
• Trim nails when they are soft and don't cut too far down.
• Select non-toxic polishes and minimize use of harsh removers.
• Replace stress-relief activities with stress balls to break nail-biting habits.
• Smoking stains nails with nicotine and damages overall nail condition.

The UK Health Security Agency (UKHSA) has declared a national outbreak of Salmonella in the UK, with health officials suspecting a possible link to imported eggs.

According to the UKHSA, 207 confirmed cases were detected between August 11, 2025, and August 1, 2026, with the majority reported in 2026. Of those affected, 38% were admitted to hospital, and one person has died.

Where Have Cases Been Reported?

Cases have been reported across the UK:

• England: 199 cases
• Scotland: 6 cases
• Wales: 1 case
• Northern Ireland: 1 case

Among cases in England, London reported 47 cases, the highest number, followed by Yorkshire and the Humber with 38 cases.

Imported Eggs Suspected as Possible Source

The UKHSA identified an increase in Salmonella Enteritidis infections caused by a single strain through whole-genome sequencing (WGS) data.

The agency has launched an investigation to identify the source of the outbreak. Initial findings suggest that the outbreak may be linked to eggs imported from outside the UK. However, the source has not been definitively established, and investigations are continuing.

Dr Kathleen O'Reilly, Associate Professor at the London School of Hygiene & Tropical Medicine, said the investigation involves identifying additional cases and examining possible common sources of infection.

Dr Damien Tully, Associate Professor at the Medical Research Council at LSHTM's Uganda Research Unit, added that the number of confirmed cases is likely to be “just the tip of the iceberg.”

What Is Salmonella?

Salmonella is a bacterial infection that commonly causes diarrhea and gastrointestinal illness.

Common symptoms include:

• Diarrhea
• Stomach cramps
• Vomiting
• Fever

Salmonella is generally a self-limiting infection. However, young children, older adults and people with weakened immune systems can develop more severe complications.

These may include bloodstream infections, infections at other sites, sepsis and multiorgan failure.

How Does Salmonella Spread?

The UKHSA stated that Salmonella Enteritidis is the most common Salmonella serovar in England and a leading cause of salmonellosis.

Like other non-typhoidal Salmonella infections, it can spread through contaminated food, including:

• Eggs
• Poultry
• Meat
• Unpasteurized dairy products
• Fresh produce

The bacteria can also spread through contact with contaminated environments or from person to person.

How To Reduce Salmonella Risk

Dr O'Reilly advised fully cooking eggs before eating them and maintaining good food hygiene.

Key precautions include:

• Cook eggs thoroughly, including omelettes that remain runny.
• Wash your hands with soap after handling food and during food preparation.
• Clean chopping boards and utensils after preparing food.
• Check food hygiene ratings when choosing catering outlets.

People who develop diarrhea or stomach cramps should rest and drink plenty of fluids. Young children, older adults and other vulnerable people who become ill should seek medical advice.

Salmonella Outbreak in US

The US is also experiencing a Salmonella outbreak linked to eggs. The US Food and Drug Administration (FDA) upgraded the recall to its highest risk level and classified nearly 1.6 million dozen eggs as “Class I.” The agency defines a Class I recall as a situation in which there is a reasonable probability that exposure to the affected product could cause serious adverse health consequences or death.

The FDA said illness usually occurs 12 to 72 hours after consuming food contaminated with Salmonella, with symptoms typically lasting four to seven days.

For people living with alopecia areata, hair loss can be unpredictable, persistent, and difficult to treat. Now, amid lack of a definitive cure, a medicine originally developed for inflammatory diseases such as rheumatoid arthritis, is showing striking results in patients with severe alopecia areata.

Two large Phase III clinical trials involving 1,399 adults and adolescents found that the drug upadacitinib significantly improved scalp hair regrowth compared with placebo. The trial’s findings were published in JAMA Dermatology.

The results are both striking and promising as alopecia areata is an autoimmune condition, in which the immune system mistakenly attacks hair follicles.

How Can An Arthritis Drug Help Hair Grow?

Upadacitinib, sold under the brand name Rinvoq, belongs to a class of medicines called JAK inhibitors.

JAK proteins help transmit signals that are involved in immune and inflammatory responses. In alopecia areata, abnormal immune response contributes to the attack on hair follicles.

By blocking JAK1 signaling, upadacitinib can slow down some of these immune responses, potentially allowing damaged or suppressed hair follicles to resume producing hair for some time.

The drug is already used for other autoimmune conditions including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

Its potential use in alopecia is an example of drug repurposing, where an existing medicine gets used for a completely different disease.

Also read: Going Slow & Steady Really Help With Sustainable Weight Loss? New Study Challenges The Norm

How Much Hair Did Patients Regrow?

The Phase III programme included two parallel trials, UP-AA1 and UP-AA2, involving adults and adolescents with severe alopecia areata.

After 24 weeks, about 45% of patients taking 15 mg of upadacitinib achieved at least 80% scalp hair coverage. More than 54% of those taking 30 mg reached the same threshold.

In comparison, only about 2% of placebo recipients achieved that level of regrowth.

Researchers also reported improvements in eyebrow and eyelash hair and indirectly in quality of life

Strikingly, benefits were seen in people with severe disease, rather than only those with a few small bald patches. Severe alopecia areata in the trials was defined as hair loss affecting at least half of the scalp.

Also read: Meniscus Tears: Why Runners & Athletes Shouldn't Ignore This Common Knee Injury

What Does This Mean For Alopecia Areata Treatment?

Alopecia areata currently has no guaranteed permanent cure. And this trial does not mean that the condition can be cured.

The disease can follow a relapsing and unpredictable course, with hair growing back and then falling out again.

The new findings show that upadacitinib can promote substantial hair regrowth while patients are receiving treatment. They do not prove that the underlying autoimmune disease can be permanently eliminated.

There are already approved JAK inhibitors for alopecia areata, including baricitinib, ritlecitinib and deuruxolitinib, so upadacitinib would not be the first drug in this category.

Side Effects

The safety findings in the trials were consistent with the known safety profile of upadacitinib, and researchers reported no new safety concerns during the study period.

Common adverse events included upper respiratory infections, acne, increased creatine phosphokinase and nasopharyngitis.

But JAK inhibitors are powerful medicines that regulates immune system and are not something people should take simply because they are experiencing hair loss. Their risks and benefits need to be assessed by a doctor.